All tumor cells are the offspring of a single, aberrant cell, but they are not all alike. Only a few retain the capacity of the original cell to create an entire tumor. Such cancer stem cells can migrate to other tissues and become fatal metastases. To fully cure a patient's cancer, it is crucial to find and eliminate all of these cells because any that escape can regenerate the tumor and trigger its spread through the body.
Liang Fang and his colleagues in Walter Birchmeier's group at the Max Delbrück Center for Molecular Medicine (MDC), working with colleagues on the Berlin-Buch campus, have now discovered a molecule that interrupts biochemical signals essential for the survival of a certain type of cancer stem cell. The work is published ahead of print in the online edition of Cancer Research.
A new inhibitor suppresses tumor growth and cancer stem cells. The image on the left shows beta catenin (red) in cell nuclei indicating that these are cancer stem cells. The image on the right shows that the new substance successfully removed beta catenin from the nuclei.
Picture by Liang Fang for the MDC
In their study Liang and his colleagues focused on a biochemical network within cells called the Wnt signaling pathway, which Birchmeier's lab has studied for many years. One of their discoveries has been that certain types of cancer stem cells require continual stimulation via this pathway to survive and maintain the properties that make them so dangerous.
A component of the network called beta-catenin plays an essential role in transmitting Wnt signals to genes that promote the survival and reproduction of the cancer cells. In healthy cells there is no signal from Wnt, and beta-catenin is destroyed.
"In the absence of a signal, beta-catenin is locked out of the cell nucleus," Birchmeier says. "It is linked to a complex of proteins that ultimately break it down. Normally it requires a signal to be released from this 'destruction complex,' and it travels to the cell nucleus." There beta-catenin binds to transcription factors such as the protein TCF4, and in combination the molecules activate specific target genes. In cancer there is no signal, but defective cellular molecules behave as if they have received one and release beta-catenin from the complex.
It might be possible, the scientists reasoned, to prevent this by interrupting the interaction between beta-catenin and TCF4 with a drug. Contacts between two proteins are normally very difficult to destabilize with the small molecules that make up drugs. Proteins usually bind over large areas of their surfaces, which means that a comparatively small obstacle won't prevent the interaction. That is the case with other beta-catenin binding partners.
But the crucial points of contact between beta-catenin and TCF4 appeared to be small "hotspots" which suggested that an inhibitor might block it. Liang Fang took the problem to the campus Screening Unit and Medicinal Chemistry group, a partnership between the MDC and FMP. The facility has high-throughput technology platforms and a "library" of tens of thousands of substances that scientists use to search for inhibitors. The screen turned up a compound they called LF3 which very strongly inhibited binding.
After showing that the compound stripped cancer stem cells of some properties essential to their survival, the lab's next step was to determine whether it would have any effect on tumors in living animals. The scientists turned to the company EPO, a campus-based spin-off of the MDC, to develop lines of mice with tumors derived from human colon cancer tissue. The company specializes in creating mouse models from individual patients' tumors, then testing the animals with a battery of known drugs in hopes of finding one that will effectively combat a specific case of cancer. In this case, all the animals developed tumors, even when injected with a relatively small number of enriched cancer cells.
The animals were then treated with LF3. "We observed a strong reduction of tumor growth," Walter Birchmeier says. "What remained seemed to be completely devoid of cancer stem cells - LF3 seemed to be powerfully triggering these cells to differentiate into benign tissue. At the same time no signaling systems other than Wnt were disturbed. All of these factors make LF3 very promising to further develop as a lead compound, aiming for therapies that target tumors whose growth and survival depend on Wnt signaling."
Reference: Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, von Kries JP, Birchmeier W. A small-molecule antagonist of the β-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis. Cancer Res. 2015 Dec 8. doi: canres.1519.2015.
Josef Zens | EurekAlert!
Toward a 'smart' patch that automatically delivers insulin when needed
18.01.2017 | American Chemical Society
127 at one blow...
18.01.2017 | Stiftung Zoologisches Forschungsmuseum Alexander Koenig, Leibniz-Institut für Biodiversität der Tiere
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences